QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in th...

 benzinga-bulls-and-bears-intel-fedex-cracker-barrel--and-markets-close-at-record-highs

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

Core News & Articles

Wells Fargo analyst Derek Archila downgrades aTyr Pharma (NASDAQ:ATYR) from Overweight to Equal-Weight and lowers the price ...

Core News & Articles

RBC Capital analyst Brian Abrahams downgrades aTyr Pharma (NASDAQ:ATYR) from Outperform to Sector Perform and lowers the pri...

Core News & Articles

HC Wainwright & Co. analyst Joseph Pantginis downgrades aTyr Pharma (NASDAQ:ATYR) from Buy to Neutral.

 atyr-pharma-stock-sinks-plans-fda-review-after-mixed-phase-3-results

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung f...

Core News & Articles

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although c...

Core News & Articles

Jefferies analyst Roger Song maintains aTyr Pharma (NASDAQ:ATYR) with a Buy and raises the price target from $9 to $17.

Core News & Articles

– SEC Filing

Core News & Articles

aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION